SIRUS PHARMACEUTICALS
SIRUS PHARMACEUTICALS
Industry:
Artificial Intelligence Biotechnology Health Care Pharmaceutical
Status:
Active
Similar Organizations
Ayerst Pharmaceuticals
Ayerst Pharmaceuticals was added in 2013.
Cann Pharmaceuticals
Cann Pharmaceuticals
Fujisawa Healthcare
Subsidiaries of Fujisawa Pharmaceutical Co.
Fujisawa Research Institute of America
Subsidiaries of Fujisawa Pharmaceutical Co.
TiENLAND
Australian Pharmaceutical Health Products
Upjohn Pharmaceuticals
Upjohn Pharmaceuticals is a pharmaceutical manufacturing company.
Current Employees Featured
More informations about "Sirus Pharmaceuticals"
Sirus Company Profile 2024: Valuation, Investors, Acquisition
Sirus General Information Description. Operator of a pharmaceutical research company. The company focuses on drug development for the treatment of nerve injury and muscle spasm by โฆSee details»
Sirus Pharmaceuticals Ltd - Drug pipelines, Patents, Clinical trials ...
Explore Sirus Pharmaceuticals Ltd with its drug pipeline, therapeutic area, technology platform, , Drug:SGX-311, SRSS-016, SRSC-371, SRSS-021, SRSA-366. Biomedical products DataSee details»
Arakis Acquires Sirus, Gains Access To Sublingual Platform
Mar 31, 2004 LONDON - Arakis Ltd. embarked on its third funding round to raise £25 million (US$45.5 million) or more, and acquired privately held Sirus Pharmaceuticals Ltd. in an all โฆSee details»
Sirus | VentureRadar
Sirus VentureRadar profile. Find out more about Sirus including the VentureRadar Innovation and Growth scores, Similar Companies and more. ... Ardena Belgium n/a Ardena is a fully โฆSee details»
Sirus Pharmaceuticals - Contacts, Employees, Board Members
Organization. Sirus Pharmaceuticals . Connect to CRM . Save . Summary. People. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. Sirus Pharmaceuticals has โฆSee details»
Sirius Pharmaceuticals | Company Profile | The Company Check
Jun 26, 2024 Sirius Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 October 1991 and has a history of 33 years โฆSee details»
Sirus Pharmaceuticals - Crunchbase
Sirus Pharmaceuticals Ltd. Start Free Trial . Chrome ExtensionSee details»
Sirus Pharmaceuticals Ltd. - BioCentury Company Profiles - BCIQ
Sirus Pharmaceuticals Ltd. - BioCentury Company Profiles for the biopharma industrySee details»
Sirus Pharmaceuticals Ltd:Board โฆ
Discovery Company profile page for Sirus Pharmaceuticals Ltd including technical research,competitor monitor,market trends,company profile& stock symbolSee details»
SGX-311 - Drug Targets, Indications, Patents - Synapse
SGX-311, Initially developed by Sirus Pharmaceuticals Ltd, Now, its global highest R&D status is Discontinued, Therapeutic Areas: Nervous System Diseases. ... Originator Organization. Sirus โฆSee details»
SIRUS PHARMACEUTICALS LTD innovation strategy - GoodIP
SIRUS PHARMACEUTICALS LTD has a total of 16 patent applications. Its first patent ever was published in 1995. It filed its patents most often in United Kingdom, Australia and WIPO (World โฆSee details»
SGX-511 - Drug Targets, Indications, Patents - Synapse - Patsnap
SGX-511, Initially developed by Sirus Pharmaceuticals Ltd, Now, its global highest R&D status is Discontinued, Therapeutic Areas: Nervous System Diseases. ... Originator Organization. Sirus โฆSee details»
Francesca Crawford - Chief Executive Officer - Crunchbase
Sirus Pharmaceuticals Team Member. Ethical Holdings Team Member. Organization Name . Title At Company . Start Date . End Date . Altacor . Founder & CEO: Apr 2006: Jul 2017: Spirogen . โฆSee details»
SGX-211 - Drug Targets, Indications, Patents - Synapse - Patsnap
SGX-211: a Sodium channels blockers Drug, Initially developed by Sirus Pharmaceuticals Ltd, Now, its global highest R&D status is Discontinued, Mechanism: Sodium channels blockers, โฆSee details»
Sirus Therapeutics announces positive signals from Phase I siRNA โฆ
Dec 10, 2024 Joint US and China-based healthcare firm Sirius Therapeuticsโs SRSD107 was safe and well tolerated in a Phase I first-in-human trial. The treatment under clinical โฆSee details»
SRSA-360 - Drug Targets, Indications, Patents - Synapse
SRSA-360, Initially developed by Sirus Pharmaceuticals Ltd, Now, its global highest R&D status is Discontinued, Therapeutic Areas: Nervous System Diseases. Biomedical products. Data. โฆSee details»
Sirius Therapeutics - Crunchbase Company Profile & Funding
Also Known As Jingyin Pharmaceutical, SiriusRNA, ้ๅ ่ฏไธ, Sirius Therapeutics, Inc. Legal Name Jingyin Pharmaceutical (Shanghai) Co., Ltd. Company Type For Profit; Contact Email โฆSee details»
SRSS-025 - Drug Targets, Indications, Patents - Synapse - Patsnap
SRSS-025, Initially developed by Sirus Pharmaceuticals Ltd, Now, its global highest R&D status is Discontinued, Therapeutic Areas: Nervous System Diseases,Other Diseases. ... Originator โฆSee details»
SRSS-023 - Drug Targets, Indications, Patents - Synapse - Patsnap
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.See details»